• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by IsoPlexis Corporation

    3/21/23 9:10:11 AM ET
    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ISO alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-40894
    Issuer: IsoPlexis Corp
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 35 NE Industrial Rd
    Branford CONNECTICUT 06405
    Telephone number: 475-282-1703
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Common stock
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2023-03-21 By Tara Petta AVP
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ISO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ISO

    DatePrice TargetRatingAnalyst
    2/15/2022$17.00 → $12.00Overweight
    Morgan Stanley
    1/27/2022$20.00 → $15.00Outperform
    SVB Leerink
    11/19/2021$24.00Outperform
    Evercore ISI Group
    11/11/2021$17.00 → $20.00Outperform
    SVB Leerink
    11/2/2021$17.00Outperform
    SVB Leerink
    11/2/2021Outperform
    Cowen & Co.
    11/2/2021$16.00Overweight
    Morgan Stanley
    More analyst ratings

    $ISO
    Financials

    Live finance-specific insights

    See more
    • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

      Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire

      12/21/22 4:49:03 PM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

      Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, Calif. and BRANFORD, Conn., Dec. 21, 2022 /PRNewswire/ -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire IsoP

      12/21/22 4:15:00 PM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • IsoPlexis to Report Third Quarter 2022 Financial Results on November 10, 2022

      BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report financial results for the third quarter 2022 before market open on Thursday, November 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event. About IsoPlexis IsoPlexis is empowering labs to leverage the ce

      10/19/22 7:00:00 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company

      PhenomeX to begin trading under symbol (NASDAQ:CELL) EMERYVILLE, Calif., March 21, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health. The newly combined company has been renamed PhenomeX and its common stock will begin trading on Nasdaq under the ticker symbol "CELL" at market open tomorrow. PhenomeX is positioned to be the leading

      3/21/23 8:02:00 AM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • IsoPlexis Reports Preliminary Full Year 2022 Revenue

      BRANFORD, Conn., Jan. 12, 2023 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced its preliminary unaudited revenue for the full year ended December 31, 2022. Total revenue for the full year ended December 31, 2022 is expected to be in the range of $16.6 to $16.8 million, representing a decrease of approximately 3% to 4% compared to $17.3 million for the full year ended December 31, 2021. Fourth quarter results were lower than expected primarily due to the timing of customer orders for instruments and lower consumable sales, as the previously described macroeconomic head

      1/12/23 4:05:00 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

      Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire

      12/21/22 4:49:03 PM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $ISO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by IsoPlexis Corporation (Amendment)

      SC 13D/A - IsoPlexis Corp (0001615055) (Subject)

      6/15/23 4:15:39 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by IsoPlexis Corporation (Amendment)

      SC 13G/A - IsoPlexis Corp (0001615055) (Subject)

      2/14/23 4:33:58 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by IsoPlexis Corporation (Amendment)

      SC 13G/A - IsoPlexis Corp (0001615055) (Subject)

      2/14/23 2:40:05 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    Leadership Updates

    Live Leadership Updates

    See more
    • IsoPlexis Appoints Key Financial and Legal Hires from Leading Tools and Omics Companies

      BRANFORD, Conn., Nov. 30, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced the appointment of Richard Rew as Senior VP, General Counsel and Secretary; Raj Khakhar as VP of Finance; and Manny Resendes as Global Controller. These three new appointments further strengthen Isoplexis' financial and legal teams. "We are excited to have Mr. Rew, Mr. Khakhar, and Mr. Resendes join our team at IsoPlexis," said Sean Mackay, CEO of IsoPlexis. "These recent hires will strengthen our ability to accelerate our growth trajectory a

      11/30/21 7:00:00 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IsoPlexis Bolsters Its Global Operational and Product Support Leadership

      BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company. Michelle Reid, Ph.D. joins IsoPlexis as VP of Service and Support, and Anthony Catalano joins as the Senior VP of Operations. With these appointments, IsoPlexis continues to strengthen its operations and product support teams, providing high need proteomic products with highly customer centric support. Ms. Reid comes to IsoPlexis with over 20 years of experience leading and devel

      11/12/21 7:00:00 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IsoPlexis Bolsters Its Global Operational and Product Support Leadership

      BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company. Michelle Reid, Ph.D. joins IsoPlexis as VP of Service and Support, and Anthony Catalano joins as the Senior VP of Operations. With these appointments, IsoPlexis continues to strengthen its operations and product support teams, providing high need proteomic products with highly customer centric support. Ms. Reid comes to IsoPlexis with over 20 years of experience leading and devel

      11/12/21 7:00:00 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Khakhar Rajesh T.

      4 - IsoPlexis Corp (0001615055) (Issuer)

      3/21/23 5:04:56 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Myers Jason W.

      4 - IsoPlexis Corp (0001615055) (Issuer)

      3/21/23 4:53:55 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Ho Gregory P.

      4 - IsoPlexis Corp (0001615055) (Issuer)

      3/21/23 4:52:06 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley reiterated coverage on IsoPlexis with a new price target

      Morgan Stanley reiterated coverage of IsoPlexis with a rating of Overweight and set a new price target of $12.00 from $17.00 previously

      2/15/22 10:15:01 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SVB Leerink reiterated coverage on IsoPlexis with a new price target

      SVB Leerink reiterated coverage of IsoPlexis with a rating of Outperform and set a new price target of $15.00 from $20.00 previously

      1/27/22 4:33:30 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Evercore ISI Group initiated coverage on IsoPlexis with a new price target

      Evercore ISI Group initiated coverage of IsoPlexis with a rating of Outperform and set a new price target of $24.00

      11/19/21 7:09:33 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    SEC Filings

    See more
    • SEC Form 15-12G filed by IsoPlexis Corporation

      15-12G - IsoPlexis Corp (0001615055) (Filer)

      3/31/23 8:32:18 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IsoPlexis Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits

      8-K - IsoPlexis Corp (0001615055) (Filer)

      3/22/23 8:13:01 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 POS filed by IsoPlexis Corporation

      S-8 POS - IsoPlexis Corp (0001615055) (Filer)

      3/21/23 5:20:43 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care